Compare iShares MSCI South Korea ETF (EWY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Natera Inc. Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $149.85 (market cap $22.66B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.5× iShares MSCI South Korea ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and Natera Inc. Common Stock for 0 Days on average.
| EWY | NTRA | |
|---|---|---|
Market Cap | $22.66B | $57.03B |
Volume | 17,900,400 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $425.64 |
52-Week Low | $85.17 | $179.42 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $166.56, down 2.16% amid broader Asian market pressures from rising oil prices and U.S. bond yields. Technical indicators show a bearish trend with strong selling signals from moving averages and oscillators, though RSI levels suggest potential oversold conditions. The ETF remains heavily concentrated in semiconductor giants Samsung and SK hynix, benefiting from AI-driven memory demand but vulnerable to sector volatility.
Outlook hinges on AI infrastructure spending and memory cycle strength, with corporate earnings showing resilience. Risks include high concentration in two stocks, geopolitical tensions, and sensitivity to global interest rates. Near-term support at $166 could test investor confidence if macroeconomic pressures persist.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
